Search
01/09/2025
Integration of Artificial Intelligence-Enhanced Capsule Endoscopy in Clinical Practice: A Review of Market-Available Tools for Clinical Practice
Giordano, A, Romero-Mascarell, C, González-Suárez, B, Guarner-Argente, C. Integration of Artificial Intelligence-Enhanced Capsule Endoscopy in Clinical Practice: A Review of Market-Available Tools for Clinical Practice. DIGESTIVE DISEASES AND SCIENCES. 2025; 70(9)DOI:10.1007/s10620-025-09099-4. PMID:40490597. IF:2.500(Q2/5D).
01/09/2025
ANCA associated pulmonary fibrosis: vasculitis or not vasculitis
Codes-Méndez, H, Castillo, D, Moya-Alvarado, P, Giménez-Palleiro, A, Castellvi, I. ANCA associated pulmonary fibrosis: vasculitis or not vasculitis. CURRENT OPINION IN PULMONARY MEDICINE. 2025; 31(5)DOI:10.1097/MCP.0000000000001187. PMID:40548517. IF:2.800(Q2/5D).
01/09/2025
Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992-2024)
Jenei, K, Hahn, G, Kesselheim, AS, Tibau, A. Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992-2024). Journal Of Cancer Policy. 2025; 45DOI:10.1016/j.jcpo.2025.100597. PMID:40472969. IF:(Q/D).
01/09/2025
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
Remon, J, Bironzo, P, Girard, N, Bigay-Game, L, Juan-Vidal, O, de Castro, J, Reguart, N, Greillier, L, Cousin, S, Dansin, E, Majem, M, Bernabe, R, Martinez, JM, Diaz, M, Meya, A, Alcalá-López, D, Garcia-Sanz, A, Righi, L, Novello, S, Besse, B. Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00300-6. PMID:40907517. IF:35.900(Q1/1D).
01/09/2025
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
Tombal, B, Choudhury, A, Saad, F, Gallardo, E, Soares, A, Loriot, Y, Mcdermott, R, Rodriguez-Vida, A, Velho, PI, Nolè, F, Cruz, F, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Veiga, FG, Skoneczna, I, Trindade, KMD, Carcano, FM, Lecouvet, F, Coens, C, Poncet, C, Fournier, B, Gillessen, S, Crua, F. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. ANNALS OF ONCOLOGY. 2025; 36(9)DOI:10.1016/j.annonc.2025.05.011. PMID:40450503. IF:65.400(Q1/1D).
01/09/2025
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis
Mcloughlin, MA, Kovilakam, SC, Dunn, WG, Gu, MX, Tobin, J, Pershad, Y, Williams, N, Leongamornlert, D, Dawson, K, Bond, L, Marando, L, Wen, S, Wilson, R, Valenzano, G, Symeonidou, V, Rak, J, Damaskou, A, Gozdecka, M, Liu, XX, Barcena, C, Nomdedeu, J, Costeas, P, Dimitriou, ID, Fiorillo, E, Orrù, V, de Almeida, JG, Mckerrell, T, Cullen, M, Mohorianu, I, Foukaneli, T, Warren, AJ, Wong, C, Follows, G, Godfrey, AL, Gudgin, E, Cucca, F, Mckinney, E, Baxter, EJ, Gerstung, M, Mitchell, J, Wiseman, D, Bick, AG, Fabre, M, Quiros, PM, Nangalia, J, Kar, S, Vassiliou, GS. Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis. NATURE GENETICS. 2025; 57(9)DOI:10.1038/s41588-025-02296-x. PMID:40877435. IF:29.000(Q1/1D).